-
1
-
-
0032542389
-
Lipoprotein(a) as a risk factor for coronary artery disease
-
discussion 86U
-
Marcovina S.M., Koschinsky M.L. Lipoprotein(a) as a risk factor for coronary artery disease. Am J Cardiol 1998, 82(12A):57U-66U. discussion 86U.
-
(1998)
Am J Cardiol
, vol.82
, Issue.12 A
, pp. 57U-66U
-
-
Marcovina, S.M.1
Koschinsky, M.L.2
-
2
-
-
84896543027
-
Lipoprotein(a): the underestimated cardiovascular risk factor
-
Thompson G.R., Seed M. Lipoprotein(a): the underestimated cardiovascular risk factor. Heart 2014, 100(7):534-535.
-
(2014)
Heart
, vol.100
, Issue.7
, pp. 534-535
-
-
Thompson, G.R.1
Seed, M.2
-
3
-
-
47649091099
-
A new serum type system in man-the Lp system
-
Berg K. A new serum type system in man-the Lp system. Acta Pathol Microbiol Scand 1963, 59:369-382.
-
(1963)
Acta Pathol Microbiol Scand
, vol.59
, pp. 369-382
-
-
Berg, K.1
-
4
-
-
0031005739
-
Invivo transfer of lipoprotein(a) into human atherosclerotic carotid arterial intima
-
Nielsen L.B., Gronholdt M.L., Schroeder T.V., Stender S., Nordestgaard B.G. Invivo transfer of lipoprotein(a) into human atherosclerotic carotid arterial intima. Arterioscler Thromb Vasc Biol 1997, 17(5):905-911.
-
(1997)
Arterioscler Thromb Vasc Biol
, vol.17
, Issue.5
, pp. 905-911
-
-
Nielsen, L.B.1
Gronholdt, M.L.2
Schroeder, T.V.3
Stender, S.4
Nordestgaard, B.G.5
-
5
-
-
67651210632
-
Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality
-
Emerging Risk Factors Collaboration
-
Erqou S., Kaptoge S., Perry P.L., Di Angelantonio E., Thompson A., White I.R., et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009, 302(4):412-423. Emerging Risk Factors Collaboration.
-
(2009)
JAMA
, vol.302
, Issue.4
, pp. 412-423
-
-
Erqou, S.1
Kaptoge, S.2
Perry, P.L.3
Di Angelantonio, E.4
Thompson, A.5
White, I.R.6
-
6
-
-
1842829035
-
Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models
-
Boffa M.B., Marcovina S.M., Koschinsky M.L. Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models. Clin Biochem 2004, 37(5):333-343.
-
(2004)
Clin Biochem
, vol.37
, Issue.5
, pp. 333-343
-
-
Boffa, M.B.1
Marcovina, S.M.2
Koschinsky, M.L.3
-
7
-
-
84871674237
-
Lipoprotein(a): resurrected by genetics
-
Kronenberg F., Utermann G. Lipoprotein(a): resurrected by genetics. J Intern Med 2013, 273(1):6-30.
-
(2013)
J Intern Med
, vol.273
, Issue.1
, pp. 6-30
-
-
Kronenberg, F.1
Utermann, G.2
-
8
-
-
0025311925
-
Lipoprotein (a). Heterogeneity and biological relevance
-
Scanu A.M., Fless G.M. Lipoprotein (a). Heterogeneity and biological relevance. J Clin Invest 1990, 85(6):1709-1715.
-
(1990)
J Clin Invest
, vol.85
, Issue.6
, pp. 1709-1715
-
-
Scanu, A.M.1
Fless, G.M.2
-
9
-
-
84898025084
-
Lipoprotein(a) in various conditions: to keep a sense of proportions
-
Kronenberg F. Lipoprotein(a) in various conditions: to keep a sense of proportions. Atherosclerosis 2014, 234(1):249-251.
-
(2014)
Atherosclerosis
, vol.234
, Issue.1
, pp. 249-251
-
-
Kronenberg, F.1
-
10
-
-
0023393811
-
Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma
-
Utermann G., Menzel H.J., Kraft H.G., Duba H.C., Kemmler H.G., Seitz C. Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J Clin Invest 1987, 80(2):458-465.
-
(1987)
J Clin Invest
, vol.80
, Issue.2
, pp. 458-465
-
-
Utermann, G.1
Menzel, H.J.2
Kraft, H.G.3
Duba, H.C.4
Kemmler, H.G.5
Seitz, C.6
-
11
-
-
77951637599
-
Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants
-
Erqou S., Thompson A., Di Angelantonio E., Saleheen D., Kaptoge S., Marcovina S., et al. Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants. J Am Coll Cardiol 2010, 55(19):2160-2167.
-
(2010)
J Am Coll Cardiol
, vol.55
, Issue.19
, pp. 2160-2167
-
-
Erqou, S.1
Thompson, A.2
Di Angelantonio, E.3
Saleheen, D.4
Kaptoge, S.5
Marcovina, S.6
-
12
-
-
84893853699
-
Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin)
-
Khera A.V., Everett B.M., Caulfield M.P., Hantash F.M., Wohlgemuth J., Ridker P.M., et al. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). Circulation 2014, 129(6):635-642.
-
(2014)
Circulation
, vol.129
, Issue.6
, pp. 635-642
-
-
Khera, A.V.1
Everett, B.M.2
Caulfield, M.P.3
Hantash, F.M.4
Wohlgemuth, J.5
Ridker, P.M.6
-
13
-
-
84885954764
-
Lipoprotein(a) concentrations, isoform size, and risk of type 2 diabetes: a Mendelian randomisation study
-
Kamstrup P.R., Nordestgaard B.G. Lipoprotein(a) concentrations, isoform size, and risk of type 2 diabetes: a Mendelian randomisation study. Lancet Diabetes Endocrinol 2013, 1(3):220-227.
-
(2013)
Lancet Diabetes Endocrinol
, vol.1
, Issue.3
, pp. 220-227
-
-
Kamstrup, P.R.1
Nordestgaard, B.G.2
-
14
-
-
84872876060
-
Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography
-
Safarova M.S., Ezhov M.V., Afanasieva O.I., Matchin Y.G., Atanesyan R.V., Adamova I.Y., et al. Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography. Atheroscler Suppl 2013, 14(1):93-99.
-
(2013)
Atheroscler Suppl
, vol.14
, Issue.1
, pp. 93-99
-
-
Safarova, M.S.1
Ezhov, M.V.2
Afanasieva, O.I.3
Matchin, Y.G.4
Atanesyan, R.V.5
Adamova, I.Y.6
-
15
-
-
67049167090
-
Genetically elevated lipoprotein(a) and increased risk of myocardial infarction
-
Kamstrup P.R., Tybjaerg-Hansen A., Steffensen R., Nordestgaard B.G. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 2009, 301(22):2331-2339.
-
(2009)
JAMA
, vol.301
, Issue.22
, pp. 2331-2339
-
-
Kamstrup, P.R.1
Tybjaerg-Hansen, A.2
Steffensen, R.3
Nordestgaard, B.G.4
-
16
-
-
84893333521
-
Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population
-
Kamstrup P.R., Tybjaerg-Hansen A., Nordestgaard B.G. Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol 2014, 63(5):470-477.
-
(2014)
J Am Coll Cardiol
, vol.63
, Issue.5
, pp. 470-477
-
-
Kamstrup, P.R.1
Tybjaerg-Hansen, A.2
Nordestgaard, B.G.3
-
17
-
-
35148892823
-
European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts)
-
Graham I., Atar D., Borch-Johnsen K., Boysen G., Burell G., Cifkova R., et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2007, 28(19):2375-2414.
-
(2007)
Eur Heart J
, vol.28
, Issue.19
, pp. 2375-2414
-
-
Graham, I.1
Atar, D.2
Borch-Johnsen, K.3
Boysen, G.4
Burell, G.5
Cifkova, R.6
-
18
-
-
8844246477
-
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
-
Grundy S.M., Cleeman J.I., Merz C.N., Brewer H.B., Clark L.T., Hunninghake D.B., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Arterioscler Thromb Vasc Biol 2004, 24(8):e149-e161.
-
(2004)
Arterioscler Thromb Vasc Biol
, vol.24
, Issue.8
, pp. e149-e161
-
-
Grundy, S.M.1
Cleeman, J.I.2
Merz, C.N.3
Brewer, H.B.4
Clark, L.T.5
Hunninghake, D.B.6
-
19
-
-
78649888517
-
Lipoprotein(a) as a cardiovascular risk factor: current status
-
Nordestgaard B.G., Chapman M.J., Ray K., Boren J., Andreotti F., Watts G.F., et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010, 31(23):2844-2853.
-
(2010)
Eur Heart J
, vol.31
, Issue.23
, pp. 2844-2853
-
-
Nordestgaard, B.G.1
Chapman, M.J.2
Ray, K.3
Boren, J.4
Andreotti, F.5
Watts, G.F.6
-
20
-
-
2442520797
-
Efficacy of extended-release niacin with lovastatin for hypercholesterolemia: assessing all reasonable doses with innovative surface graph analysis
-
Insull W., McGovern M.E., Schrott H., Thompson P., Crouse J.R., Zieve F., et al. Efficacy of extended-release niacin with lovastatin for hypercholesterolemia: assessing all reasonable doses with innovative surface graph analysis. Arch Intern Med 2004, 164(10):1121-1127.
-
(2004)
Arch Intern Med
, vol.164
, Issue.10
, pp. 1121-1127
-
-
Insull, W.1
McGovern, M.E.2
Schrott, H.3
Thompson, P.4
Crouse, J.R.5
Zieve, F.6
-
21
-
-
84877299845
-
HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment
-
Hps Thrive Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013, 34(17):1279-1291.
-
(2013)
Eur Heart J
, vol.34
, Issue.17
, pp. 1279-1291
-
-
-
22
-
-
84904252744
-
Effects of extended-release niacin with laropiprant in high-risk patients
-
Hps Thrive Collaborative Group. Landray M.J., Haynes R., Hopewell J.C., Parish S., Aung T., Tomson J., et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 2014, 371(3):203-212.
-
(2014)
N Engl J Med
, vol.371
, Issue.3
, pp. 203-212
-
-
Landray, M.J.1
Haynes, R.2
Hopewell, J.C.3
Parish, S.4
Aung, T.5
Tomson, J.6
-
24
-
-
84864239186
-
Therapeutic potential of mipomersen in the management of familial hypercholesterolaemia
-
Gelsinger C., Steinhagen-Thiessen E., Kassner U. Therapeutic potential of mipomersen in the management of familial hypercholesterolaemia. Drugs 2012, 72(11):1445-1455.
-
(2012)
Drugs
, vol.72
, Issue.11
, pp. 1445-1455
-
-
Gelsinger, C.1
Steinhagen-Thiessen, E.2
Kassner, U.3
-
25
-
-
84870065743
-
Emerging therapeutic agents to lower lipoprotein(a) levels
-
Kolski B., Tsimikas S. Emerging therapeutic agents to lower lipoprotein(a) levels. Curr Opin Lipidol 2012, 23(6):560-568.
-
(2012)
Curr Opin Lipidol
, vol.23
, Issue.6
, pp. 560-568
-
-
Kolski, B.1
Tsimikas, S.2
-
26
-
-
84892679366
-
Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation against LDL-C (OSLER) randomized trial
-
Koren M.J., Giugliano R.P., Raal F.J., Sullivan D., Bolognese M., Langslet G., et al. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation against LDL-C (OSLER) randomized trial. Circulation 2014, 129(2):234-243.
-
(2014)
Circulation
, vol.129
, Issue.2
, pp. 234-243
-
-
Koren, M.J.1
Giugliano, R.P.2
Raal, F.J.3
Sullivan, D.4
Bolognese, M.5
Langslet, G.6
-
27
-
-
0036959309
-
Intraindividual comparison of two extracorporeal LDL apheresis methods: lipidfiltration and HELP
-
Julius U., Metzler W., Pietzsch J., Fassbender T., Klingel R. Intraindividual comparison of two extracorporeal LDL apheresis methods: lipidfiltration and HELP. Int J Artif Organs 2002, 25(12):1180-1188.
-
(2002)
Int J Artif Organs
, vol.25
, Issue.12
, pp. 1180-1188
-
-
Julius, U.1
Metzler, W.2
Pietzsch, J.3
Fassbender, T.4
Klingel, R.5
-
28
-
-
0032790486
-
Three low density lipoprotein apheresis techniques in treatment of patients with familial hypercholesterolemia: a long-term evaluation
-
Richter W.O., Donner M.G., Schwandt P. Three low density lipoprotein apheresis techniques in treatment of patients with familial hypercholesterolemia: a long-term evaluation. Ther Apher 1999, 3(3):203-208.
-
(1999)
Ther Apher
, vol.3
, Issue.3
, pp. 203-208
-
-
Richter, W.O.1
Donner, M.G.2
Schwandt, P.3
-
29
-
-
84894257728
-
Does regular lipid apheresis in patients with isolated elevated lipoprotein(a) levels reduce the incidence of cardiovascular events?
-
Rosada A., Kassner U., Vogt A., Willhauck M., Parhofer K., Steinhagen-Thiessen E. Does regular lipid apheresis in patients with isolated elevated lipoprotein(a) levels reduce the incidence of cardiovascular events?. Artif Organs 2014, 38(2):135-141.
-
(2014)
Artif Organs
, vol.38
, Issue.2
, pp. 135-141
-
-
Rosada, A.1
Kassner, U.2
Vogt, A.3
Willhauck, M.4
Parhofer, K.5
Steinhagen-Thiessen, E.6
-
30
-
-
84889577512
-
Lipoprotein apheresis: an update
-
Julius U., Fischer S., Hohenstein B., Bornstein S.R. Lipoprotein apheresis: an update. Clin Lipodol 2013, 8(6):693-705.
-
(2013)
Clin Lipodol
, vol.8
, Issue.6
, pp. 693-705
-
-
Julius, U.1
Fischer, S.2
Hohenstein, B.3
Bornstein, S.R.4
-
31
-
-
72649086379
-
Designing a study to evaluate the effect of apheresis in patients with elevated lipoprotein(a)
-
Kassner U., Vogt A., Rosada A., Barz F., Giannakidou-Jordan E., Berthold H.K., et al. Designing a study to evaluate the effect of apheresis in patients with elevated lipoprotein(a). Atheroscler Suppl 2009, 10(5):85-88.
-
(2009)
Atheroscler Suppl
, vol.10
, Issue.5
, pp. 85-88
-
-
Kassner, U.1
Vogt, A.2
Rosada, A.3
Barz, F.4
Giannakidou-Jordan, E.5
Berthold, H.K.6
-
32
-
-
72649100270
-
Treatment of symptomatic HyperLp(a)lipoproteinemia with LDL-apheresis: a multicentre study
-
Stefanutti C., D'Alessandri G., Russi G., De Silvestro G., Zenti M.G., Marson P., et al. Treatment of symptomatic HyperLp(a)lipoproteinemia with LDL-apheresis: a multicentre study. Atheroscler Suppl 2009, 10(5):89-94.
-
(2009)
Atheroscler Suppl
, vol.10
, Issue.5
, pp. 89-94
-
-
Stefanutti, C.1
D'Alessandri, G.2
Russi, G.3
De Silvestro, G.4
Zenti, M.G.5
Marson, P.6
-
33
-
-
84872848174
-
Lipoprotein apheresis: state of the art and novelties
-
Stefanutti C., Julius U. Lipoprotein apheresis: state of the art and novelties. Atheroscler Suppl 2013, 14(1):19-27.
-
(2013)
Atheroscler Suppl
, vol.14
, Issue.1
, pp. 19-27
-
-
Stefanutti, C.1
Julius, U.2
-
34
-
-
61549101898
-
Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events
-
Jaeger B.R., Richter Y., Nagel D., Heigl F., Vogt A., Roeseler E. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med 2009, 6(3):229-239.
-
(2009)
Nat Clin Pract Cardiovasc Med
, vol.6
, Issue.3
, pp. 229-239
-
-
Jaeger, B.R.1
Richter, Y.2
Nagel, D.3
Heigl, F.4
Vogt, A.5
Roeseler, E.6
-
35
-
-
84890904215
-
Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study
-
Leebmann J., Roeseler E., Julius U., Heigl F., Spitthoever R., Heutling D., et al. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study. Circulation 2013, 128(24):2567-2576.
-
(2013)
Circulation
, vol.128
, Issue.24
, pp. 2567-2576
-
-
Leebmann, J.1
Roeseler, E.2
Julius, U.3
Heigl, F.4
Spitthoever, R.5
Heutling, D.6
-
36
-
-
84872841551
-
Differences in the atherogenic risk of patients treated by lipoprotein apheresis according to their lipid pattern
-
von Dryander M., Fischer S., Passauer J., Muller G., Bornstein S.R., Julius U. Differences in the atherogenic risk of patients treated by lipoprotein apheresis according to their lipid pattern. Atheroscler Suppl 2013, 14(1):39-44.
-
(2013)
Atheroscler Suppl
, vol.14
, Issue.1
, pp. 39-44
-
-
von Dryander, M.1
Fischer, S.2
Passauer, J.3
Muller, G.4
Bornstein, S.R.5
Julius, U.6
-
37
-
-
63349111341
-
Single lipoprotein apheresis session improves cardiac microvascular function in patients with elevated lipoprotein(a): detection by stress/rest perfusion magnetic resonance imaging
-
Bohl S., Kassner U., Eckardt R., Utz W., Mueller-Nordhorn J., Busjahn A., et al. Single lipoprotein apheresis session improves cardiac microvascular function in patients with elevated lipoprotein(a): detection by stress/rest perfusion magnetic resonance imaging. Ther Apher Dial 2009, 13(2):129-137.
-
(2009)
Ther Apher Dial
, vol.13
, Issue.2
, pp. 129-137
-
-
Bohl, S.1
Kassner, U.2
Eckardt, R.3
Utz, W.4
Mueller-Nordhorn, J.5
Busjahn, A.6
|